Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | IL4I1 | Q96RQ9 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31667509 | 0.90 | PRMT5 (0.38) | IL4I1HPGDSYKMAPK1 | |
| SCHEMBL31667193 | 0.90 | IL4I1 (0.37) | IL4I1 | |
| SCHEMBL32686815 | 0.89 | IL4I1 (0.39) | IL4I1SYK | |
| SCHEMBL31667411 | 0.88 | NOS1 (0.39) | NOS1ALDH1A1IL4I1SMN1; SMN2NPC1 | |
| SCHEMBL31667135 | 0.87 | IL4I1 (0.38) | NOS1ALDH1A1IL4I1SMN1; SMN2KDM4E | |
| SCHEMBL31667194 | 0.85 | IL4I1 (0.39) | NOS1ALDH1A1IL4I1SMN1; SMN2KDM4E | |
| SCHEMBL31667057 | 0.85 | IL4I1 (0.40) | NOS1ALDH1A1IL4I1SMN1; SMN2KDM4E | |
| SCHEMBL31667612 | 0.84 | IL4I1 (0.39) | NOS1ALDH1A1IL4I1SMN1; SMN2KDM4E | |
| SCHEMBL31667479 | 0.84 | PTDSS1 (0.40) | ALDH1A1IL4I1HPGDSYKMAPK1 | |
| SCHEMBL31667717 | 0.83 | MEN1 (0.45) | IL4I1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | NOS1 2579/4885ALDH1A1 2719/4885IL4I1 2872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.